PharmaCielo Ltd. (TSXV:PCLO)
Canada
· Delayed Price · Currency is CAD 0.0700
-0.0050 (-6.67%)
Feb 21, 2025, 3:40 PM EST
PharmaCielo Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 2.6 | 1.54 | 5.31 | 1.94 | 2.65 | 0.79 | Upgrade
|
| Revenue Growth (YoY) | -7.62% | -70.96% | 172.93% | -26.71% | 237.26% | - | Upgrade
|
| Cost of Revenue | 2.57 | 2.91 | 4.27 | 6.12 | 8.65 | 0.14 | Upgrade
|
| Gross Profit | 0.03 | -1.37 | 1.04 | -4.17 | -5.99 | 0.64 | Upgrade
|
| Selling, General & Admin | 4.13 | 6.77 | 9.45 | 19.15 | 31.7 | 28.04 | Upgrade
|
| Other Operating Expenses | 0.02 | - | - | - | - | 0.09 | Upgrade
|
| Operating Expenses | 5.96 | 8.67 | 12.12 | 20.89 | 35.86 | 31.35 | Upgrade
|
| Operating Income | -5.93 | -10.04 | -11.08 | -25.06 | -41.85 | -30.7 | Upgrade
|
| Interest Expense | -0.69 | - | - | -0.2 | - | - | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0 | 0.07 | 0.59 | Upgrade
|
| Earnings From Equity Investments | - | - | -1 | -0.47 | -0.02 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | 0.09 | -0.12 | -0.11 | 0.47 | -0.49 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.6 | -2.32 | -0.96 | -0.36 | 0.03 | -0.39 | Upgrade
|
| EBT Excluding Unusual Items | -9.23 | -12.27 | -13.15 | -26.2 | -41.31 | -31 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.03 | -0.14 | -0.43 | -0.31 | -0.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.04 | - | - | - | Upgrade
|
| Asset Writedown | -5.03 | -4.23 | -1.27 | - | -1.25 | - | Upgrade
|
| Other Unusual Items | 0.23 | 0.18 | - | - | -0.89 | -3.62 | Upgrade
|
| Pretax Income | -14.03 | -16.3 | -14.52 | -26.63 | -43.76 | -34.67 | Upgrade
|
| Net Income | -14.03 | -16.3 | -14.52 | -26.63 | -43.76 | -34.67 | Upgrade
|
| Net Income to Common | -14.03 | -16.3 | -14.52 | -26.63 | -43.76 | -34.67 | Upgrade
|
| Shares Outstanding (Basic) | 169 | 160 | 151 | 146 | 113 | 96 | Upgrade
|
| Shares Outstanding (Diluted) | 169 | 160 | 151 | 146 | 113 | 96 | Upgrade
|
| Shares Change (YoY) | 7.73% | 6.03% | 3.67% | 29.41% | 17.17% | 22.84% | Upgrade
|
| EPS (Basic) | -0.08 | -0.10 | -0.10 | -0.18 | -0.39 | -0.36 | Upgrade
|
| EPS (Diluted) | -0.08 | -0.10 | -0.10 | -0.18 | -0.39 | -0.36 | Upgrade
|
| Free Cash Flow | -3.09 | -5.17 | -10.4 | -21.21 | -28 | -35.3 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.07 | -0.15 | -0.25 | -0.37 | Upgrade
|
| Gross Margin | 1.20% | -88.78% | 19.54% | -214.49% | -225.77% | 81.77% | Upgrade
|
| Operating Margin | -228.48% | -651.38% | -208.69% | -1288.29% | -1577.02% | -3901.91% | Upgrade
|
| Profit Margin | -540.35% | -1057.09% | -273.45% | -1369.14% | -1648.73% | -4405.55% | Upgrade
|
| Free Cash Flow Margin | -118.82% | -335.01% | -195.86% | -1090.55% | -1054.97% | -4486.02% | Upgrade
|
| EBITDA | -6.53 | -9.7 | -10.7 | -24.8 | -40.81 | -29.63 | Upgrade
|
| EBITDA Margin | -251.31% | - | -201.59% | - | - | - | Upgrade
|
| D&A For EBITDA | -0.59 | 0.34 | 0.38 | 0.26 | 1.04 | 1.08 | Upgrade
|
| EBIT | -5.93 | -10.04 | -11.08 | -25.06 | -41.85 | -30.7 | Upgrade
|
| EBIT Margin | -228.48% | - | -208.69% | - | - | - | Upgrade
|
| Revenue as Reported | 2.6 | 1.54 | 5.31 | 1.94 | 2.65 | 0.79 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.